New drug combo shows promise for rare blood disorder

NCT ID NCT04328727

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding eltrombopag (a platelet booster) to standard immune-suppressing drugs (r-ATG and cyclosporine A) helps patients with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. Thirty-six East-Asian adults and children who had not yet been treated took part. The main goal was to see how many achieved normal blood counts by 26 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eltrombopag (a drug that boosts platelet production), rabbit anti-thymocyte globulin (an immune-suppressing drug), and cyclosporine A (an immune-suppressing drug)
What this could lead to: If successful, this combination could help more patients with severe aplastic anemia achieve normal blood counts, reducing the need for transfusions and improving quality of life.
What could go wrong: This is a small, early-phase study (36 patients) with no control group, so results may not apply broadly. The drugs can cause serious side effects like infections or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA (SAA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aplastic anemia aplastic anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE APLASTIC ANEMIA (SAA)

Contacts and locations

Locations

Novartis Investigative Site

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site

Zhengzhou, Henan, 450052, China
Novartis Investigative Site

Nanchang, Jiangxi, 330006, China
Novartis Investigative Site

Changchun, Jilin, 130021, China
Novartis Investigative Site

Tianjin, 300020, China
Novartis Investigative Site

Tianjin, 300052, China
Novartis Investigative Site

Nagoya, Aichi-ken, 466 8560, Japan
Novartis Investigative Site

Fukuoka, Fukuoka, 812-8582, Japan
Novartis Investigative Site

Chuo Ku, Tokyo, 104 8560, Japan
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Seoul, 06351, South Korea
Novartis Investigative Site

Kaohsiung City, 83301, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.